SCHEMBL5652578

SCHEMBL5652578

CCOc1cc(C(=O)NN2CCCCC2)ccc1-c1nc2cc(Cl)c(F)cc2[nH]1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT2 Q8IXJ6 1/20 0.42
SIRT1 Q96EB6 1/20 0.42
SYK P43405 1/20 0.40
ITK Q08881 1/20 0.40
PLG P00747 2/20 0.39
PLAU P00749 2/20 0.39
F10 P00742 1/20 0.39
HPSE Q9Y251 1/20 0.39
HTT P42858 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
MEN1 O00255 1/20 0.39
POLB P06746 1/20 0.39
KMT2A Q03164 1/20 0.39
EGLN1 Q9GZT9 1/20 0.39
CNR1 P21554 5/20 0.38
CNR2 P34972 2/20 0.38
RHEB Q15382 1/20 0.38
PRSS12 P56730 1/20 0.38
PRKAG1 P54619 1/20 0.38
PRKAA1 Q13131 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5648605 0.93 RHEB (0.45) SIRT2SIRT1PLGPLAUHPSE
SCHEMBL5650184 0.91 HPSE (0.45) SIRT2SIRT1PLGPLAUHPSE
SCHEMBL5651818 0.91 FOXO1 (0.42) SMN1; SMN2POLBCNR1CNR2RHEB
SCHEMBL5651532 0.87 KDR (0.43) MEN1KMT2AEGLN1CNR1CNR2
SCHEMBL5650806 0.86 SIRT2 (0.46) SIRT2SIRT1HPSEHTTSMN1; SMN2
SCHEMBL5650474 0.86 CNR1 (0.41) CNR1CNR2RHEBPRSS12PTGDR2
SCHEMBL5652794 0.84 PRSS12 (0.41) MEN1KMT2AEGLN1CNR1CNR2
SCHEMBL5653611 0.83 RHEB (0.49) SMN1; SMN2POLBCNR1CNR2RHEB
SCHEMBL5652493 0.83 SIRT2 (0.47) SIRT2SIRT1HPSEHTTSMN1; SMN2
SCHEMBL5648702 0.83 SIRT2 (0.47) SIRT2SIRT1HPSEHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220769-B2 Azolylbenzamides and analogues and their use for treating osteoporosis NIKEM RESEARCH S.R.L. (IT) 2007-05-22 US disclosed
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis 3-V BIOSCIENCES, INC. 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis NR0B2, NR0B1, NCOR1 SIRT2 360/4885SIRT1 300/4885SYK 613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.